Palemo Holdings
2778
Spancrete
5277
Renascience
4889
Oncolys BioPharma
4588
Kitagawa Seiki
6327
(FY)Aug 31, 2024 | (FY)Aug 31, 2023 | (FY)Aug 31, 2022 | (FY)Aug 31, 2021 | (FY)Aug 31, 2020 | |
---|---|---|---|---|---|
Operating cash flow (Indirect Method) | |||||
Cash from operating activities | 415.39%111.92M | 421.28%21.72M | -109.23%-6.76M | 3.30%73.24M | 70.9M |
Net profit before non-cash adjustment | 268.82%52.12M | 36.53%14.13M | -71.88%10.35M | 256.04%36.81M | ---23.59M |
Total adjustment of non-cash items | 2,081.07%41.03M | -86.43%1.88M | -49.78%13.86M | -58.72%27.6M | --66.86M |
-Depreciation and amortization | 3.03%13.8M | 8.66%13.39M | -5.77%12.32M | -62.23%13.08M | --34.62M |
-Disposal profit | --2.94M | --0 | ---- | ---- | --26.71M |
-Other non-cash items | 311.11%24.3M | -848.24%-11.51M | -89.41%1.54M | 162.61%14.53M | --5.53M |
Changes in working capital | 229.15%18.77M | 118.41%5.7M | -450.67%-30.97M | -68.03%8.83M | --27.63M |
-Change in receivables | -320.07%-25.44M | 147.32%11.56M | -443.23%-24.43M | -76.25%7.12M | --29.97M |
-Change in inventory | 324.21%19.9M | -63.65%-8.88M | -201.67%-5.42M | 207.35%5.33M | ---4.97M |
-Change in payables | 1,661.10%23M | 227.66%1.31M | 52.75%-1.02M | -188.15%-2.17M | --2.46M |
-Provision for loans, leases and other losses | -23.63%1.31M | 1,862.89%1.71M | 93.33%-97K | -945.35%-1.45M | --172K |
Dividends paid (cash flow from operating activities) | |||||
Dividends received (cash flow from operating activities) | |||||
Interest paid (cash flow from operating activities) | 27.62%-6.49M | 6.84%-8.97M | 1.96%-9.63M | 9.76%-9.82M | -10.89M |
Interest received (cash flow from operating activities) | 188.89%26K | -10.00%9K | -9.09%10K | -96.50%11K | 314K |
Tax refund paid | -17.57%-2.01M | 89.81%-1.71M | -4,215.48%-16.75M | 117.12%407K | -2.38M |
Other operating cash inflow (outflow) | 3,062.08%20.93M | -84.42%662K | -25.49%4.25M | -59.51%5.7M | 14.09M |
Operating cash flow | 962.32%124.38M | 140.54%11.71M | -141.53%-28.88M | -3.47%69.54M | --72.04M |
Investing cash flow | |||||
Net PPE purchase and sale | -348.11%-14.94M | 86.65%-3.33M | -1,945.62%-24.98M | 91.90%-1.22M | ---15.08M |
Net intangibles purchase and sale | 88.33%-143K | -63.33%-1.23M | ---750K | ---- | ---- |
Net investment product transactions | -471.43%-2.4M | -120.11%-420K | 348.69%2.09M | 0.00%-840K | ---840K |
Repayment of advance payments to other parties and cash income from loans | ---- | ---- | ---- | ---- | --6.6M |
Net changes in other investments | --1.4M | ---- | ---- | 93.43%-447K | ---6.8M |
Investing cash flow | -223.02%-16.08M | 78.94%-4.98M | -842.50%-23.64M | 84.45%-2.51M | ---16.12M |
Financing cash flow | |||||
Net issuance payments of debt | -213.16%-79.63M | 30.54%-25.43M | 66.24%-36.61M | -152.44%-108.43M | --206.79M |
Issuance fees | 0.00%-541K | -19.96%-541K | ---451K | ---- | ---- |
Cash dividends paid | ---1.22M | ---- | ---- | ---- | ---- |
Net other fund-raising expenses | ---- | ---1K | ---- | ---- | ---1K |
Financing cash flow | -213.41%-81.39M | 29.93%-25.97M | 65.82%-37.06M | -152.44%-108.43M | --206.78M |
Net cash flow | |||||
Beginning cash position | -4.80%381.36M | -18.28%400.6M | -7.78%490.18M | 97.90%531.51M | --268.57M |
Current changes in cash | 239.81%26.9M | 78.52%-19.24M | -116.38%-89.58M | -115.76%-41.4M | --262.7M |
Cash adjustments other than cash changes | ---1K | ---- | -102.94%-2K | -70.82%68K | --233K |
End cash Position | 7.05%408.25M | -4.80%381.36M | -18.28%400.6M | -7.78%490.18M | --531.51M |
Free cash flow | 1,428.79%109.29M | 113.09%7.15M | -179.93%-54.61M | 19.94%68.32M | --56.96M |
Currency Unit | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |